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ABSTRACT 
Background: Paraoxonase-1 (PON-1) has been suggested to be associated with cardiovascular disease 
(CVD) risk, however, aspects of the association, such as shape and independence from conventional risk 
factors are still uncertain. We aimed to assess the association of PON-1 with CVD risk and determine its 
potential utility for CVD risk prediction. 
Methods: PON-1 was measured as its arylesterase activity at baseline in the PREVEND prospective study 
of 6902 participants.  
Results: During a mean follow-up of 9.3 years, 730 CVD events were recorded. Serum PON-1 was 
weakly correlated with several cardiovascular risk markers including high-density lipoprotein cholesterol 
(HDL-C) (r=0.18; P < 0.001) and was approximately log-linearly associated with CVD risk. In analyses 
adjusted for conventional risk factors, the hazard ratio (95% CI) for CVD per 1 standard deviation (SD) 
increase in loge PON-1 was 0.92 (0.85 to 0.99; P=0.020), which remained persistent after additional 
adjustment for potential confounders 0.93 (0.86 to 0.99; P=0.037). The association was attenuated on 
further adjustment for HDL-C 0.95 (0.88 to 1.02; P=0.153). In a meta-analysis of 6 population-based 
prospective studies involving 15 064 participants and 2958 incident CVD outcomes, the pooled 
multivariable adjusted (including HDL-C) relative risk (95% CI) for CVD was 0.95 (0.90 to 1.02; 
P=0.138) per 1 SD increase in PON-1 values. Adding PON-1 to a CVD risk prediction model containing 
conventional risk factors did not improve the C-index or net reclassification. 
Conclusions: There is an approximately log-linear inverse association between PON-1 activity and CVD 
risk, which is partly dependent on HDL-C levels. In addition, serum PON-1 activity provides no 
significant improvement in CVD risk assessment beyond conventional CVD risk factors. 
 
Keywords: paraoxonase-1; cardiovascular disease; risk factor; risk prediction; meta-analysis 
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1. Introduction 
The inverse and independent association of high-density lipoprotein cholesterol (HDL-C) with 
atherosclerotic cardiovascular disease (CVD) is well known,1 and is commonly ascribed to the functional 
properties of this lipoprotein fraction.2  HDL promotes the reverse cholesterol transport pathway, by 
stimulating efflux of cholesterol out of macrophages in the arterial wall and exerts antioxidant, anti-
inflammatory, antithrombotic, and endothelial cell maintenance properties.3-6 Paraoxonase-1 (PON-1) is a 
HDL-bound esterase enzyme with well-established antioxidant functions, which is synthesized by the 
liver.7 It hydrolyses lipid peroxides, thereby protecting low-density lipoproteins (LDLs) from oxidative 
modifications. Recent studies in rodent models and humans have suggested that the anti-atherogenic and 
cardioprotective effects of the HDL fraction are primarily attributable to PON-1 activity.8 Serum PON-1 
activity has been shown to be reduced in patients with stable coronary artery disease, post-myocardial 
infarction patients, and in patients at increased CVD risk such as hypercholesterolaemia, metabolic 
syndrome, and type 2 diabetes.9-11 
Emerging evidence indicates that PON-1 activity may be linked to CVD risk. Two published 
literature-based meta-analyses have assessed the relationship between PON-1 activity and coronary heart 
disease (CHD) risk.12, 13 However, because they only compared PON-1 activity in CHD cases and non-
CHD controls, the nature, shape, and magnitude of the prospective association could not be addressed. A 
number of population-based prospective studies have generally reported inverse associations between 
PON-1 activity and CVD outcomes.14-19 Some of these reports were relatively small or did not adjust for 
potential confounders. Data on the prospective associations in approximately healthy (“general”) 
populations are also sparse. Among the limited studies that have been based in general populations, some 
reported inverse associations,15, 17 with majority reporting null associations.14, 15, 20, 21 For these reasons, the 
nature of the shape, magnitude, and independence of the association between PON-1 activity and CVD 
risk in general population settings remains uncertain. There are suggestions that PON-1 might be a better 
atherosclerotic CVD risk factor compared to HDL-C,22 and there is a growing interest in the potential 
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value of PON-1 in CVD risk prevention. There is therefore a requirement for an adequately powered and 
comprehensive assessment of the association of baseline PON-1 activity with risk of future first-ever 
CVD events using long-term observational evidence in the general population. Our primary aim was to 
characterize the shape and assess the magnitude and independence of the prospective association between 
PON-1 activity and CVD risk, using a large population-based sample of 6902 participants free from pre-
existing CVD at baseline. A secondary aim was to investigate the extent to which PON-1 activity could 
improve the prediction of first-onset CVD outcomes in general population settings when added to a 
conventional CVD risk prediction model. Finally, to contextualize these findings, we report a meta-
analysis of available published prospective evidence on the associations of baseline PON-1 activity and 
risk of CVD in general population settings. 
 
2. Materials and methods 
2.1. Participants  
The study population consisted of inhabitants living in the city of Groningen in the Netherlands. 
Subjects were participants in the Prevention of Renal and Vascular End-stage Disease (PREVEND) study, 
an observational, general population-based prospective cohort study designed to investigate the natural 
course of urinary albumin excretion and its relationship to renal disease and CVD and which began in 
1997. The description of the study design and recruitment processes have been described in detail 
previously.23 The baseline cohort (n=8592) was recruited from participants who were aged 28-75 years 
and had baseline measurements performed between 1997 and 1998. For the present analyses, participants 
with a prevalent history of CVD, liver disease, renal disease, or malignancy were excluded and the final 
cohort comprised of 6902 subjects with non-missing information on serum PON-1 activity, several CVD 
risk markers, and cardiovascular outcomes. The medical ethics committee of the University Medical 
Center Groningen approved the PREVEND study and which was conducted in accordance with the 
Declaration of Helsinki. Informed written consent was provided by each participant and was documented 
in a consent form approved by the medical ethics committee.  
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2.2. Risk factor assessment 
Baseline data on demographics, physical measurements (including anthropometrics), and 
cardiovascular risk factors were assessed during two outpatient visits by study participants. After an 
overnight fast and 15 minutes of rest, venous blood was obtained from participants. Plasma samples were 
prepared by centrifugation at 4 ºC. Sera was stored at -20 ºC and heparinized plasma samples stored at -80 
ºC from baseline collection until analysis. The analysis of serum PON-1 enzymatic activity was 
conducted in 2014 and was measured as its arylesterase activity, i.e. as the rate of hydrolysis of phenyl 
acetate into phenol, which has been described previously.24 The inter-assay CV was 8%. Arylesterase 
activity, measured with this assay, is positively correlated PON-1 enzymatic activity toward paraoxon.25 
Given the virtual absence of free PON-1 in serum, as determined by gelfiltration,26 its activity was 
essentially measured as HDL-bound PON-1 activity, which was consistent with several large-scale 
epidemiological studies of this nature. Plasma glucose, total cholesterol, apolipoproteins (Apo) A-1 and 
B, HDL-C, high sensitivity C-reactive protein (hsCRP), triglycerides, total bilirubin, serum creatinine, 
and serum cystatin C were measured using standard methods described previously.27-31 Urinary albumin 
excretion (UAE) was calculated as the mean of two 24-hour urine collections. Estimated glomerular 
filtration rate (eGFR), was calculated using the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) combined creatinine-cystatin C equation.32 Hypertension and type 2 diabetes mellitus were 
defined as previously reported.30, 31, 33  
  
2.3. Endpoint ascertainment 
The primary endpoint in our study was first-onset CVD, with subsidiary analyses of incident CHD and 
stroke endpoints. The dates and causes of death were obtained by record linkage with the Dutch Central 
Bureau of Statistics. Information on hospitalization for cardiovascular morbidity was received from 
PRISMANT, the Dutch national registry of hospital discharge diagnoses.34 Until 01-01-2009, all data 
were coded according to the International Classification of Diseases, Ninth Revision (ICD-9). After this 
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date, data were coded according to ICD-10 codes. First-onset CVD was defined as the combined endpoint 
of acute myocardial infarction, acute and subacute ischemic heart disease, coronary artery bypass grafting 
or percutaneous transluminal coronary angioplasty, subarachnoid hemorrhage, intracerebral hemorrhage, 
other intracranial hemorrhage, occlusion or stenosis of the precerebral or cerebral arteries, and other 
vascular interventions such as percutaneous transluminal angioplasty or bypass grafting of peripheral 
vessels and aorta. Coronary heart disease events were defined as fatal or nonfatal myocardial infarction, 
ischemic heart disease, coronary artery bypass grafting, and percutaneous transluminal coronary 
angioplasty. Stroke events were defined as subarachnoid hemorrhage, intracerebral haemorrhage, other 
and unspecified intracranial haemorrhage, and occlusion and stenosis of precerebral or cerebral arteries. 
Further details on the definition of cardiovascular outcomes are also provided in Appendix Supplement 
1. 
 
2.4. Statistical analyses 
Prospective cohort analyses Variables that were skewed (e.g., PON-1 activity, hsCRP, triglycerides, 
creatinine, and total bilirubin) were natural logarithm (loge) transformed to achieve approximately normal 
distributions. Baseline characteristics of participants were summarized using descriptive analyses. Partial 
correlation coefficients (adjusted for age and sex) were calculated to assess the cross-sectional 
associations of serum PON-1 activity with CVD risk markers. Analyses of the association between serum 
PON-1 activity and CVD risk involved Cox proportional hazards models after confirmation of 
assumptions of proportionality of hazards.35 Shapes of the association of  PON-1 activity with CVD risk 
were assessed by plotting hazard ratios (HRs) estimated within quintiles of baseline PON-1 values 
relative to the bottom quintile against the mean loge PON-1 value in each quintile using floating absolute 
risks (FARs).36 Given the log-linear shape of the association, hazard ratios (HRs) were calculated per 1 
standard deviation (SD) higher loge serum PON-1 values. The SD of baseline loge serum PON-1 was 0.31 
(equivalent to approximately one-fold higher PON-1 activity, as e0.31=1.36). To assess the independence 
of the association, HRs were calculated with progressive adjustment for age and sex, other established 
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CVD risk factors [smoking status, history of diabetes, SBP, and total cholesterol], potential confounders 
[body mass index (BMI), alcohol consumption, fasting glucose, triglycerides, eGFR, UAE, hsCRP, and 
total bilirubin], and finally HDL-C. Effect modification by individual characteristics, such as age, sex, 
and other cardiovascular risk markers was assessed using formal tests of interaction. To limit potential 
biases due to pre-existing undiagnosed CVD (i.e. reverse causation), subsidiary analyses included 
excluding the first two years of follow-up, participants on regular anti-hypertensive medication, and 
participants on regular lipid-lowering medication (as these patients are supposed to have at least a 20% 
10-year risk of CVD37).  
We calculated measures of discrimination for censored time-to-event data (Harrell’s C-index38) and 
reclassification, to assess whether adding information on serum PON-1 values to a model that included 
conventional cardiovascular risk factors39 is associated with improvement in CVD risk prediction. To 
investigate the change in C-index, we added PON-1 to a model based on risk factors included in the 
Framingham CVD Risk Score (i.e., age, sex, smoking status, SBP, total cholesterol, and HDL-C).40 For 
participants with at least 10 years of follow-up, reclassification was assessed using the net-
reclassification-improvement (NRI).41 Reclassification analysis was based on predicted 10-year CVD risk 
categories of low (<5%), intermediate (5 to <7.5%), and high (≥7.5%) risk.42 In subsidiary analyses, we 
also performed risk discrimination and reclassification analyses based on the Reynolds Risk Score 
(RRS).43, 44 Risk prediction analysis was restricted to participants without a known history of diabetes or 
CVD at baseline.  
Literature review and meta-analysis We conducted a meta-analysis using a predefined protocol and in 
accordance with the PRISMA (Appendix Supplement 2) and MOOSE guidelines14,15 (Appendix 
Supplement 3). We sought prospective cohort studies that have assessed the association between PON-1 
activity and CVD risk published up to July 2015 using MEDLINE, EMBASE, and Science Citation Index 
databases as well as scanning reference lists from the included articles. The computer-based searches 
combined free and MeSH search terms and combination of key words related to the exposure (e.g., 
“paraoxonase-1”, “arylesterase”, etc.) and outcome (e.g., “cardiovascular disease”, “coronary heart 
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disease”, “stroke”, etc.). Further details on the search strategy are presented in Appendix Supplement 4. 
Studies were eligible if they had at least one year of follow-up and recruited participants from 
approximately general populations as previously described.45 The primary endpoint of this analysis was 
any CVD event (i.e., composite CVD, CHD, or stroke). A pooled estimate was also assessed for CHD 
outcomes. Appendix Supplement 1 provides details of study-specific endpoint definitions. Study quality 
was assessed based on the Newcastle–Ottawa Scale (NOS) method.46 
Summary measures were presented as relative risks (RRs) with 95% confidence intervals (CIs). We 
assumed hazard ratios and odds ratios to approximate the same measure of RRs. To enhance consistency, 
reported study-specific RRs were transformed to per 1SD change in baseline PON-1 values using 
standard statistical methods47, 48 which have been described in detail previously.45 The summary RR 
(including the estimate from the present study) was calculated using random effects meta-analysis. All 
statistical analyses were conducted using Stata version 14 (Stata Corp, College Station, Texas). 
 
3. Results 
Results from the PREVEND cohort 
3.1. Baseline Characteristics and Correlates of paraoxonase-1 Activity 
Data were available for 6902 participants without a known history of CVD at baseline. The mean age 
of overall participants at baseline was 48 (SD 12) years and 52% were women.  (Table 1). Mean (SD) 
loge PON-1 value was 3.97 (0.31) U/L. Loge PON-1 values were weakly correlated with physical 
measures (BMI, waist-to-hip ratio, and blood pressure), as well as several lipid markers, but not with total 
bilirubin. The strongest correlations were observed for HDL-C (r = 0.18) and Apo-A1 (r = 0.17). Baseline 
PON-1 values were higher by 6% in current alcohol consumers compared with non-consumers. Values 
were lower by 6% in people with diabetes compared with people without diabetes and by 14% in people 
on regular glucose lowering medication compared with non-users (Table 2).  
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3.2. Paraoxonase-1 Activity and Risk of Incident CVD 
During an average follow-up of 9.3 years (64 407 person-years at risk), 730 incident CVD events 
(annual rate 11.2/1000 person-years at risk, 95% confidence interval [CI]: 10.4 to 12.1) were recorded. 
An approximately log-linear relationship was observed between PON-1 activity and CVD risk, in 
analyses adjusted for established CVD risk factors and potential confounders (Figure 1). The HR for 
CVD per 1 SD increase in loge PON-1 was 0.90 (95% CI, 0.84 to 0.97; P=0.004) in age- and sex-adjusted 
analyses, which remained consistent in analyses adjusted for established factors 0.92 (95% CI, 0.85 to 
0.99; P=0.020) and additional adjustment for BMI, alcohol consumption, glucose, loge triglycerides, 
eGFR, loge UAE, and loge total bilirubin 0.93 (95% CI: 0.86 to 0.99; P=0.037). The results were 
somewhat attenuated after additional adjustment for HDL-C 0.95 (95% CI, 0.88 to 1.02; P=0.153) (Table 
3). In an age- and sex-adjusted analysis, the initial association 0.90 (95% CI, 0.84 to 0.97; P=0.004) was 
attenuated after single additional adjustment for HDL-C 0.96 (95% CI, 0.89 to 1.03; P=0.249). 
Substituting total cholesterol and HDL-C for apolipoproteins B and A-1 respectively resulted in similar 
associations (data not shown). HRs were similar in analyses that excluded CVD outcomes recorded in the 
first two years of follow-up, participants on regular antihypertensive medication, and participants on 
regular lipid-lowering medication (Table 4). The associations did not vary significantly by levels or 
categories of several clinically relevant individual characteristics, except for suggestion of effect 
modification by BMI (P for interaction = 0.026) and smoking (P for interaction = 0.053) (Figure 2).  In 
separate analyses for CHD and stroke, the approximately log-linear inverse association of PON-1 with 
CHD in analyses adjusted for several established risk factors and potential confounders was somewhat 
attenuated on additional adjustment for HDL-C (Table 3; Figure 3) and there was no statistically 
significant evidence of an association with stroke (Table 3). To put the strength of the association of 
PON-1 activity with CVD risk into context, direct comparisons were made to associations of HDL-C with 
CVD, CHD, and stroke outcomes. Serum HDL-C concentrations were inversely and independently 
associated with CVD and CHD outcomes. The associations were also independent of serum PON-1 
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activity. There was no evidence of an association with stroke outcomes (Table 5). Similar findings were 
found in analysis with Apo A-I instead of HDL-C (data not shown). 
 
3.3. Paraoxonase-1 Activity and CVD Risk Prediction 
Addition of HDL-C measurements to a prognostic model for first cardiovascular events that included 
data on age, sex, smoking status, blood pressure, and total cholesterol increased the C-index by 0.0034 
(0.0003 to 0.0064; P=0.02). The C-index increased non-significantly by 0.0003 (-0.0005 to 0.0011; 
P=0.49) on further addition of information on serum PON-1 to this model, yielding a NRI of 0.75% (-
0.02 to 1.52%; P=0.06) for the predicted 10-year CVD risk categories (Appendix Supplement 5). There 
were no differences in the C-index according to clinically relevant individual level characteristics (data 
not shown). There was no significant improvement in risk discrimination and reclassification when RR 
risk score components were used (Appendix Supplement 6). 
 
Literature-based meta-analyses 
3.4. Literature Search, Characteristics, and Quality of Eligible Studies 
The initial search identified 1986 potentially relevant citations. After screening and detailed assessment, 
5 articles based on 5 unique population-based studies were included (Figure 4). Therefore we meta-
analyzed estimates from 6 studies (including the current study) involving a total of 15 064 unique 
participants with 2958 incident CVD outcomes reporting on the association between PON-1 activity 
and CVD risk. Detailed characteristics of these studies and quality assessment have been summarized 
in Appendix Supplements 7-8 
 
3.5. Paraoxonase-1 Activity and CVD Risk in Pooled Analysis 
Of the six studies, three studies (including the current study) provided risk estimates for PON-1 as 
measured by its arylesterase activity (using phenyl acetate as substrate)17, 20 and the other three reported 
estimates for PON-1 as measured by paraoxonase activity (using paraoxon as substrate).15, 16, 21 Both assay 
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systems were used in two studies17, 20 (Appendix Supplement 7). Including the current study, the 
overall pooled unadjusted or age-adjusted RR (95% CI) for any CVD event per 1 SD higher PON-1 
values was 0.87 (0.80 to 0.96; P=0.005). There was substantial heterogeneity between studies (I2>70%), 
but this could not be explored in detail because of the limited number of studies. However, exclusion of 
any single study at a time from the meta-analysis had minimal effect on the pooled RRs, which ranged 
from 0.85 (0.77-0.94) to 0.91 (0.84-0.98). The combined RR excluding the single largest study was 0.86 
(0.76-0.97), very similar to the main finding. The pooled unadjusted or age-adjusted RRs were 0.77 (0.65 
to 0.93 P=0.006) and 0.95 (0.91 to 1.00; P=0.041) for PON-1 measured as its arylesterase activity and 
paraoxonase activity respectively (P for meta-regression = 0.023). The overall pooled RR in analyses 
typically adjusted for several established CVD risk factors (including HDL-C) was 0.95 (0.90 to 1.02; 
P=0.138) and the corresponding RRs were 0.90 (0.75 to 1.07; P=0.223) and 0.98 (0.93 to 1.03; P=0.368) 
for PON-1 measured as its arylesterase activity and paraoxonase activity respectively (P for meta-
regression = 0.495) (Figure 5). The pooled corresponding fully adjusted RR for CHD (5 studies; 
14,032 participants and 2,541 CHD cases) was 0.98 (0.94 to 1.02; P=0.265). There was no 
evidence of publication bias (P-value for Egger test=0.201). 
 
4. Discussion 
4.1. Summary of main findings 
Our findings in the PREVEND cohort comprising individuals without a history of CVD at baseline, 
provide several important findings that have not been previously addressed. PON-1 activity was 
correlated with several cardiovascular risk markers and more strongly with HDL-C and Apo A-1. In 
analyses adjusted for established CVD risk factors, we observed an approximately log-linear association 
of PON-1 activity with risk of CVD. The association remained consistent on further adjustment for a 
comprehensive panel of potential confounders, but was attenuated after single adjustment for HDL-C in 
both analyses initially only adjusted for age and sex and further for established and potential risk factors, 
consistent with previous reports.15, 16 In contrast, the association between HDL-C and CVD was 
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independent of PON-1 in analyses conducted in the same participants, which suggests HDL-C as a 
stronger risk indicator than PON-1. Mackness and colleagues16 have demonstrated some similar findings. 
However, additional analyses in their study suggested PON-1 as a stronger risk indicator for CVD than 
HDL-C in men with pre-existing CHD. Indeed, it has been shown that populations with pre-existing 
cardiometabolic disease have marked reductions in serum PON-1 activity without significant lower 
concentrations of HDL-C.9 The associations remained generally similar across several clinically relevant 
subgroups, except for the suggestion of effect modification by BMI and smoking status; characterized by 
an inverse association in individuals with a normal BMI category compared to a statistically non-
significant association in individuals with higher BMIs and an inverse association in smokers compared 
to a statistically non-significant association in non-smokers. Given the multiple statistical tests for 
interaction conducted, results of the subgroup analyses should be interpreted with caution and may 
require replication in further studies. The associations were similar in analyses that excluded first two 
years of follow-up, participants on regular antihypertensive medication, or participants on regular statin 
medication. Similar associations were observed for CHD risk. However, there was no statistically 
significant evidence of an association with stroke, consistent with the findings for HDL-C in the same set 
of participants. Uncertainties still exist for the association between HDL-C and stroke, particularly for 
stroke subtypes;49 however, there is a possibility that the current findings may be attributed to the low 
event rate for stroke in our study. There is also a possibility that the null findings for stroke could be due 
to the combined endpoints of different stroke subtypes, with different aetiologies. We were however 
unable to conduct separate analyses for the subtypes of stroke because of the very low event rates in each 
endpoint. Given that no previous study has evaluated the association of PON-1 activity and stroke-
specific outcomes, larger-scale studies are warranted to confirm or refute these findings. Results from 
assessments of improvements in measures of risk discrimination and reclassification, indicate that 
additional information on PON-1 measurements provides no significant improvement in CVD risk 
prediction.  
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Pooled findings from the systematic meta-analysis of the six available studies showed that PON-1 was 
inversely associated with CVD risk in unadjusted or age-adjusted analysis. In the PREVEND study, we 
measured PON-1 activity as its arylesterase activity (with phenyl acetate as substrate) which was driven 
by previous documentation that arylesterase activity is less variable between subjects compared to its 
activity towards paraoxon, and is closely correlated with PON-1 mass.7, 25 In view of this, we also 
grouped the studies included in the meta-analysis according to the type of PON-1 activity assay. Indeed, 
in unadjusted or age-adjusted analysis, the risk estimate for PON-1 as arylesterase activity was stronger 
than that of PON-1 as paraoxonase activity. Further adjustment for established risk factors (including 
HDL-C) showed a less robust association of PON-1 activity with incident CVD, confirming the 
suggestion that the inverse association between PON-1 activity and CVD risk is partly dependent on 
HDL-C concentrations. 
 
4.2. Possible explanations for findings  
Our results indicate that PON-1 is inversely associated with CVD (including CHD) risk, independent 
of several established risk factors except for HDL-C. Though the majority of previous studies conducted 
in the general population have failed to demonstrate an inverse independent association,14-16, 21 the 
dependency of the association on HDL-C has previously been reported.15, 16 The attenuation of the 
association on adjustment for HDL-C is expected, given that PON-1 is an important component of 
HDL,50-53 which acts as its carrier and site of action. Plausible biologic mechanisms by which PON-1 
contributes to reduced CVD risk is through the inhibition of LDL oxidation,54 which is believed to play a 
central role in the development of atherosclerosis.55 PON-1 is also involved in the destruction of pro-
inflammatory oxidised phospholipids (involved in the development and progression of atherosclerotic 
lesions56) which are present in oxidised LDLs,57 decreases the lipid peroxide content in arterial lesions, 
could promote cholesterol efflux, and also prevents HDL from being oxidized.58  
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4.3. Implications of findings 
The findings of our study may have several implications. Irrespective of whether addition of 
information on PON-1 to conventional risk factors provides no improvement in CVD risk prediction, its 
potential utility for CVD risk prevention and treatment has been debated. Given the potential role of 
PON-1 in the detoxification of lipid peroxides, the overall evidence supports the possibility that elevated 
PON-1 activity might protect from CVD events in the general population. Conversely, individuals with 
low PON-1 activity may have a greater risk of developing atherosclerotic CVD. Indeed, significantly 
higher rates of atherosclerosis have been demonstrated in genetic rodent models deficient in PON-1 and 
who were fed a high cholesterol diet.59 Futhermore, PON-1 overexpression inhibits atherosclerosis 
development in mice.60 Therefore, there remains a possibility that dietary or pharmacological 
interventions that preserve or increase PON-1 activity might form the basis of CVD prevention and 
treatment strategies. Dietary consumption of red wine flavonoids has been shown to preserve serum PON-
1 activity in atherosclerotic ApoE deficient mice61 and pomegranate juice (rich in flavonoids) has been 
shown to cause significant elevation in PON-1 activity in human volunteers and also substantially reduce 
the size of atherosclerotic lesions in ApoE deficient mice.62 Rigorous intervention studies in humans are 
warranted to investigate these potential therapeutic implications of PON-1. 
 
4.4. Strengths and limitations 
The strengths of the current study deserve consideration. Our study included analyses of primary data 
as well as a meta-analysis of all available published prospective cohorts in a single comprehensive 
investigation. It provides the most comprehensive investigation, to date, of the observational 
epidemiological association between PON-1 activity and CVD risk. PREVEND participants were selected 
from a sample that was nationally representative, were well characterized, involved a high response and 
follow-up rates and had been prospectively monitored using established hospital admissions databases 
and disease endpoints. The PREVEND database had measurements on a comprehensive panel of lifestyle 
and biological markers that permitted adequate adjustment for potential confounders, hence enabling 
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reliable assessments of the magnitude of associations. The current study had higher statistical power to 
examine the associations in greater detail, including comparison of the associations at different levels or 
categories of vascular risk factors and sensitivity analyses to supplement and contextualize the principal 
findings. Individuals with prevalent CVD at baseline were excluded from the analyses, therefore limiting 
any possibilities of reverse-causation bias. The PREVEND study participants were suitable for risk 
prediction analyses because they were followed for a long duration and had complete set of measurements 
used in standard risk prediction scores. We also carried out several sensitivity analyses to avoid potential 
bias due to undiagnosed disease at baseline. Despite these, residual biases (i.e., reverse causation) may 
still remain because of the possibility of subclinical or undetected prevalent disease.  On the other hand, 
the present analysis also has some limitations. In the PREVEND cohort, given the nature of the 
observational data available, there is a possibility of potential residual confounding due to errors in 
measurements of risk marker and other unmeasured confounders. Measurements of PON-1 in the 
PREVEND study involved prolonged serum storage, which could have resulted in under-estimation of the 
associations due to sample degradation. However, PON-1 is known to show no loss of activity by 
prolonged storage in frozen samples (-70°C) and on repeated freeze-thawing over two years, with an 
approximate loss in activity by 20% over seven years.63 In our analyses, we were unable to show the 
extent to which baseline PON-1 measurements may underestimate the association between long-term 
PON-1 activity and CVD outcomes, because of the absence of repeat measurements on PON-1.  The 
analyses were based on a predominantly white-European population, therefore the findings may not be 
generalisable to individuals of different ethnicities, given that interpopulation differences in serum 
paraoxonase specific activity (which are independent of differences in serum lipids and lipoprotein 
concentrations) have been demonstrated in healthy populations.64 There was substantial heterogeneity 
between the contributing studies for the meta-analysis and the limited number of studies precluded 
detailed exploration of heterogeneity; however, our results remained robust in several sensitivity analyses. 
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5. Conclusions 
In conclusion, there is an approximately log-linear inverse association between PON-1 activity and 
CVD risk, which is partly dependent on HDL-C levels. In the general population, adding information on 
PON-1 to conventional CVD risk factors provides no significant improvement in CVD risk prediction. 
17 
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Figure 1. Hazard ratios for incident cardiovascular disease by baseline values of loge paraoxonase-1 
using floating absolute risks 
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A, Unadjusted; B, adjusted for age and sex; C, adjustment as in B plus smoking status, history of 
diabetes, systolic blood pressure, and total cholesterol; D, adjustment as in C plus body mass index, 
alcohol consumption, glucose, loge triglycerides, estimated glomerular filtration rate (as calculated using 
the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation), loge 
urine albumin excretion, and loge total bilirubin; E, adjustment as in D plus high-density lipoprotein 
cholesterol; the size of the box is proportional to the inverse of the variance of hazard ratio 
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Figure 2. Hazard ratios for cardiovascular disease per 1 SD increase in baseline loge paraoxonase-1 
values, by several participant level characteristics 
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Hazard ratios were adjusted for age, sex, smoking status, history of diabetes, systolic blood pressure, and 
total cholesterol; CI, confidence interval (bars); CVD, cardiovascular disease; Estimated GFR, glomerular 
filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined 
creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; SD, 
standard deviation; *, P-value for interaction; cut-offs used for body mass index, systolic blood pressure, 
total cholesterol, HDL-C, triglycerides, estimated GFR, and total bilirubin  are median values. 
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Figure 3. Hazard ratios for incident coronary heart disease by baseline values of loge paraoxonase-1 
activity using floating absolute risks 
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A, Unadjusted; B, adjusted for age and sex; C, adjustment as in B plus smoking status, history of 
diabetes, systolic blood pressure, and total cholesterol; D, adjustment as in C plus body mass index, 
alcohol consumption, glucose, loge triglycerides, estimated glomerular filtration rate (as calculated using 
the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation), loge 
urine albumin excretion, and loge total bilirubin; E, adjustment as in D plus high-density lipoprotein 
cholesterol; the size of the box is proportional to the inverse of the variance of hazard ratio 
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Figure 4. Selection of studies included in the meta-analysis 
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Figure 5. Relative risks for cardiovascular disease per 1 SD higher baseline paraoxonase-1 in published 
prospective studies 
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Study acronyms are provided in Appendix Supplement 1. The summary estimates were calculated using 
random effects models; A, results were unadjusted or adjusted for age only; B, results were adjusted for 
established cardiovascular risk factors including high-density lipoprotein cholesterol; Size of data markers 
are proportional to the inverse of the variance of the relative risk; CI, confidence interval (bars); CVD, 
cardiovascular disease; RR, relative risk; SD, standard deviation 
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Table 1. Baseline participant characteristics 
 Overall (N=6,902) 
Mean (SD) or median 
(IQR) or n (%) 
Without CVD (N=6,172) 
Mean (SD) median (IQR) 
or n (%) 
With CVD (N=730) 
Mean (SD) or median 
(IQR) or n (%) 
    
Paraoxonase-1 (U/L) 53.5 (43.5-65.3) 53.8 (43.7-65.7) 50.7 (41.3-61.6) 
    
Questionnaire    
Males 3,321 (48.1) 2,836 (46.0) 485 (66.4) 
Age at survey (years) 48 (12) 47 (12) 59 (10) 
History of diabetes 211 (3.1) 148 (2.4) 63 (8.6) 
Current smokers 4,779 (69.2) 4,195 (68.0) 584 (80.0) 
Alcohol consumption    
    None 1,693 (24.5) 1,475 (23.9) 218 (29.9) 
    1-4 drinks per month 1,073 (15.6) 974 (15.8) 99 (13.6) 
    2-7 drinks per week 2,387 (34.6) 2,154 (34.9) 233 (31.9) 
    1-3 drinks per day 1,389 (20.1) 1,251 (20.3) 138 (18.9) 
    ≥ 4 drinks per day 360 (5.2) 318 (5.2) 42 (5.8) 
History of hypertension 690 (10.0) 514 (8.3) 176 (24.1) 
Regular use of anti-hypertensive medication 753 (10.9) 566 (9.2) 187 (25.6) 
Regular use of diabetic medication 67 (1.0) 42 (0.7) 25 (3.4) 
Regular use of lipid-lowering medication 173 (2.5) 121 (2.0) 52 (7.1) 
    
Physical measurements    
BMI (kg/m2) 26 (4) 26 (4) 27 (4) 
WHR 0.88 (0.09) 0.87 (0.09) 0.93 (0.09) 
SBP (mmHg) 128 (19) 126 (19) 144 (23) 
DBP (mmHg) 74 (10) 73 (9) 80 (10) 
    
Lipid markers    
Total cholesterol (mmol/l) 5.63 (1.12) 5.57 (1.11) 6.07 (1.04) 
HDL-C (mmol/l) 1.34 (0.40) 1.35 (0.40) 1.21 (0.38) 
Triglycerides (mmol/l) 1.13 (0.83-1.66) 1.11 (0.81-1.62) 1.40 (0.99-2.04) 
Apo A-I (g/l) 1.39 (0.30) 1.39 (0.30) 1.34 (0.29) 
Apo B (g/l) 1.02 (0.31) 1.01 (0.31) 1.15 (0.30) 
    
Metabolic, inflammatory, and liver markers    
hsCRP (mg/l) 1.21 (0.53-2.82) 1.13 (0.50-2.68) 2.10 (1.00-4.70) 
Glucose (mmol/l) 4.82 (1.09) 4.76 (0.95) 5.29 (1.82) 
Creatinine (µmol/l) 82 (73-91) 81 (73-90) 88 (77-99) 
Cystatine C (mg/dl) 0.79 (0.19) 0.78 (0.19) 0.89 (0.23) 
eGFR (ml/min/1.73 m2) 100.8 (39.0) 102.4 (39.7) 87.7 (29.6) 
Total bilirubin (µmol/l) 7 (5-9) 7 (5-9) 7 (5-9) 
UAE (mg/24 hours) 9.19 (6.25-16.59) 8.85 (6.14-15.26) 14.27 (8.13-38.70) 
    
Framingham 2008 10-year CVD risk    
    0%-< 10% 4,167 (60.4) 3,694 (59.9) 473 (64.8) 
    10%-< 20% 814 (11.8) 781 (12.7) 33 (4.5) 
    ≥ 20% 1,921 (27.8) 1,697 (27.5) 224 (30.7) 
    
RRS 10-year CVD risk    
    0%-< 10% 6,225 (90.2) 5,749 (93.2) 476 (65.2) 
    10%-< 20% 510 (7.4) 340 (5.5) 170 (23.3) 
    ≥ 20% 167 (2.4) 83 (1.3) 84 (11.5) 
 
Apo A-I, apolipoprotein A-I; Apo B, apolipoprotein B; BMI, body mass index; CVD, cardiovascular disease; hsCRP, high sensitivity C-reactive protein; DBP, 
diastolic blood pressure; eGFR, estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined 
creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; RRS, Reynolds Risk Score; SBP, systolic blood pressure; 
UAE, urinary albumin excretion; WHR, waist-to-hip ratio 
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Table 2. Cross-sectional correlates of paraoxonase-1 activity 
 
Pearson correlation 
r (95% CI)† 
Percentage difference (95% CI) in paraoxonase-1 values 
per 1 SD higher or compared to reference category of 
correlate‡ 
   
Loge Paraoxonase-1 (U/L) - - 
   
Questionnaire   
Sex   
    Female - Ref 
    Male - -4% (-5, -3)*** 
Age at survey (years) -0.08 (-0.10, -0.06)*** -2% (-3, -2)*** 
History of diabetes   
    No - Ref 
    Yes - -6% (-10, -2)* 
Smoking status   
    Non-smokers - Ref 
    Current smokers - -1% (-3, 0) 
Alcohol consumption   
    Non-consumers - Ref 
    Current consumers - 6% (4, 8)*** 
History of hypertension   
    No - Ref 
    Yes - -2% (-4, 1) 
Regular use of anti-hypertensive medication   
    No - Ref 
    Yes - -2% (-5, 0) 
Regular use of diabetic medication   
    No - Ref 
    Yes - -14% (-20, -7)*** 
Regular use of lipid-lowering medication   
    No - Ref 
    Yes - 0% (-4, 5) 
   
Physical measurements   
BMI (kg/m2) 0.00 (-0.02, 0.02) 0% (-1, 1) 
WHR -0.02 (-0.04, 0.01)*** -1% (-2, 0) 
SBP (mmHg) 0.05 (0.02, 0.07) 2% (1, 3)*** 
DBP (mmHg) 0.05 (0.03, 0.08) 2% (1, 3)*** 
   
Lipid markers   
Total cholesterol (mmol/l) 0.12 (0.10, 0.14)*** 4% (3, 5)*** 
HDL-C (mmol/l) 0.18 (0.16, 0.20)*** 6% (6, 7)*** 
Log triglycerides (mmol/l) 0.08 (0.06, 0.10)** 3% (2, 3)*** 
Apo A-I (g/l) 0.17 (0.15, 0.20)*** 6% (5, 7)*** 
Apo B (g/l) 0.04 (0.02, 0.07) 1% (1, 2)** 
   
Metabolic and inflammatory markers   
Loge hsCRP (mg/l) -0.03 (-0.05, -0.01)** -1% (-2, -0)* 
Glucose (mmol/l) -0.04 (-0.07, -0.02)*** -1% (-2, -1)** 
Loge creatinine (µmol/l) 0.03 (0.00, 0.05)* 1% (0, 2)* 
Cystatine C (mg/dl) -0.05 (-0.08, -0.03)*** -2% (-3, -1)*** 
eGFR (ml/min/1.73 m2) 0.02 (-0.00, 0.04) 1% (-0, 1)** 
Loge total bilirubin (µmol/l) 0.01 (-0.02, 0.03) 0% (-1, 1) 
Loge UAE (mg/24 hours) 0.02 (-0.00, 0.04) 1% (-0, 1) 
   
Framingham 2008 10-year CVD risk   
    0%-< 20% - Ref 
    ≥ 20% - 2% (0, 5)* 
   
RRS 10-year CVD risk   
    0%-< 20% - Ref 
    ≥ 20% - -6% (-11, -1)* 
 
Apo A-I, apolipoprotein A-I; Apo B, apolipoprotein B; BMI, body mass index; hsCRP, high sensitivity C-reactive protein; CVD, cardiovascular disease; DBP, 
diastolic blood pressure; eGFR, estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined 
creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; Ref, reference; RRS, Reynolds Risk Score; SD, standard deviation; SBP, systolic blood 
pressure; UAE, urinary albumin excretion; WHR, waist-to-hip ratio 
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Asterisks indicate the level of statistical significance: *, p<0.05; **, p<0.01; ***, p<0.001; †, Pearson correlation coefficients between loge paraoxonase-1 and the row variables; ‡, 
Percentage change in paraoxonase-1 values per 1 SD increase in the row variable (or for categorical variables, the percentage difference in mean paraoxonase-1 values for the category 
versus the reference) adjusted for age and sex;  
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Table 3. Associations of serum paraoxonase-1 activity with incident CVD, CHD and stroke 
Models CVD  CHD  Stroke  
 Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
 6,902 participants and  
730 cases 
 6,902 participants and  
390 cases 
 6,902 participants and  
153 cases 
 
Model 1 0.83 (0.78 to 0.89) < 0.001 0.82 (0.75 to 0.90) < 0.001 0.79 (0.67 to 0.92) 0.002 
Model 2 0.90 (0.84 to 0.97) 0.004 0.89 (0.81 to 0.98) 0.016 0.87 (0.74 to 1.01) 0.068 
Model 3 0.92 (0.85 to 0.99) 0.020 0.90 (0.82 to 0.99) 0.029 0.89 (0.76 to 1.04) 0.142 
Model 4 0.93 (0.86 to 0.99) 0.037 0.91 (0.83 to 1.00) 0.058 0.91 (0.78 to 1.07) 0.257 
Model 5 0.95 (0.88 to 1.02) 0.153 0.96 (0.87 to 1.07) 0.471 0.89 (0.76 to 1.05) 0.158 
 
Hazard ratios are reported per 1 standard deviation increase in loge paraoxonase-1 activity; CHD, coronary heart disease; 
CVD, cardiovascular disease 
Model 1: Unadjusted 
Model 2: Age and sex 
Model 3: Age, sex, smoking status, history of diabetes, systolic blood pressure, and total cholesterol 
Model 4: Model 3 plus body mass index, alcohol consumption, fasting glucose, loge triglycerides, estimated glomerular 
filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C 
equation), loge urinary albumin excretion, and loge total bilirubin 
Model 5: Model 4 plus high-density lipoprotein cholesterol 
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Table 4: Hazard ratios for cardiovascular disease with first two years of follow-up, participants on regular antihypertensive medication, and participants on 
regular lipid-lowering medication excluded 
 
 Events/Total Model 1  Model 2  Model 3  Model 4  Model 5  
  Hazard ratio (95% CI) P-value Hazard ratio (95% 
CI) 
P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
Excluding the first two 
years of follow-up 
720 / 6,891 0.83 (0.78 to 0.89) < 0.001 0.90 (0.84 to 0.96) 0.003 0.92 (0.85 to 0.98) 0.017 0.92 (0.86 to 0.99) 0.033 0.94 (0.88 to 1.02) 0.136 
Excluding participants 
on regular 
antihypertensive 
medication 
536 / 6,149 0.84 (0.77 to 0.91) < 0.001 0.89 (0.82 to 0.97) 0.007 0.90 (0.83 to 0.97) 0.010 0.90 (0.83 to 0.98) 0.018 0.93 (0.86 to 1.02) 0.117 
Excluding participants 
on regular lipid-
lowering medication 
670 / 6,729 0.83 (0.76 to 0.89) < 0.001 0.90 (0.83 to 0.96) 0.003 0.91 (0.84 to 0.98) 0.014 0.92 (0.85 to 0.99) 0.024 0.94 (0.87 to 1.02) 0.125 
 
Hazard ratios are reported per 1 standard deviation increase in loge paraoxonase-1 activity 
Model 1: Unadjusted 
Model 2: Age and sex 
Model 3: Age, sex, smoking status, history of diabetes, systolic blood pressure, and total cholesterol 
Model 4: Model 3 plus body mass index, alcohol consumption, fasting glucose, loge triglycerides, estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease 
Epidemiology Collaboration combined creatinine-cystatin C equation), loge urinary albumin excretion, and loge total bilirubin 
Model 5: Model 4 plus high-density lipoprotein cholesterol 
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Table 5. Associations of high-density lipoprotein cholesterol with incident CVD, CHD and stroke 
Models CVD  CHD  Stroke  
 Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
 6,902 participants and  
730 cases 
 6,902 participants and  
390 cases 
 6,902 participants and  
153 cases 
 
Model 1 0.68 (0.62 to 0.73) < 0.001 0.56 (0.49 to 0.63) < 0.001 0.90 (0.76 to 1.06) 0.205 
Model 2 0.69 (0.64 to 0.76) < 0.001 0.57 (0.50 to 0.64) < 0.001 0.95 (0.80 to 1.12) 0.507 
Model 3 0.83 (0.76 to 0.91) < 0.001 0.71 (0.62 to 0.80) < 0.001 1.12 (0.94 to 1.34) 0.202 
Model 4 0.84 (0.76 to 0.94) 0.002 0.67 (0.57 to 0.78) < 0.001 1.13 (0.91 to 1.39) 0.265 
Model 5 0.86 (0.77 to 0.96) 0.006 0.68 (0.58 to 0.80) < 0.001 1.16 (0.94 to 1.44) 0.161 
 
Hazard ratios are reported per 1 standard deviation increase in high-density lipoprotein cholesterol; CHD, coronary heart disease; 
CVD, cardiovascular disease 
Model 1: Unadjusted 
Model 2: Age and sex 
Model 3: Age, sex, smoking status, history of diabetes, systolic blood pressure, and total cholesterol 
Model 4: Model 3 plus body mass index, alcohol consumption, fasting glucose, loge triglycerides, estimated glomerular filtration 
rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation), loge 
urinary albumin excretion, and loge total bilirubin 
Model 5: Model 4 plus loge paraoxonase-1 
 
 
 
 
 
 
 
 
 
 
  
 
